|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Human EphB6 ORF mammalian expression plasmid, C-GFPSpark tag||HG10197-ACG|
|Human EphB6 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||HG10197-ACR|
|Human EphB6 ORF mammalian expression plasmid, C-Flag tag||HG10197-CF|
|Human EphB6 ORF mammalian expression plasmid, C-His tag||HG10197-CH|
|Human EphB6 ORF mammalian expression plasmid, C-Myc tag||HG10197-CM|
|Human EphB6 ORF mammalian expression plasmid, C-HA tag||HG10197-CY|
|Human EphB6 Gene cDNA clone plasmid||HG10197-M|
|Human EphB6 ORF mammalian expression plasmid, N-Flag tag||HG10197-NF|
|Human EphB6 ORF mammalian expression plasmid, N-His tag||HG10197-NH|
|Human EphB6 ORF mammalian expression plasmid, N-Myc tag||HG10197-NM|
|Human EphB6 ORF mammalian expression plasmid, N-HA tag||HG10197-NY|
|Human EphB6 natural ORF mammalian expression plasmid||HG10197-UT|
|Learn more about expression Vectors|
Ephrins are divided into the ephrin-A (EFNA) class and the ephrin-B (EFNB) class based on their structures and sequence relationships. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. EphB6 is an unusual Eph receptor, lacking catalytic capacity due to alterations in its kinase domain. Interestingly, increased metastatic activity is associated with reduced EphB6 receptor expression in several tumor types, including breast cancer. This emphasizes the potential of EphB6 to act as a suppressor of cancer aggressiveness. EphB6 suppress cancer invasiveness through c-Cbl-dependent signaling, morphologic changes, and cell attachment and indicate that EphB6 may represent a useful prognostic marker and a promising target for therapeutic approaches. EphB6 can both positively and negatively regulate cell adhesion and migration, and suggest that tyrosine phosphorylation of the receptor by an Src family kinase acts as the molecular switch for the functional transition. In addition, Ephrin-B2 may be a physiological ligand for the EphB6 receptor.